Paul Evans, Principal Investigator
Paul Evans is a vascular biologist who has published >110 papers (>7000 citations; h-index=45). After training in Cambridge, he was awarded Kidney Research UK Fellowships to study the mechanisms of inflammation and discovered a novel family of anti-inflammatory deubiquitinating enzymes. This opened a new field of research with >350 papers (>150 different authors) citing his discovery of Cezanne, an enzyme that is involved in cardiovascular disease, cancer, autoimmunity and infection.
Evans was appointed a Senior Lecturer in Cardiovascular Science in 2004 at Imperial College and his laboratory focussed on mechanosensitive pathways that drive atherosclerosis. He was appointed Chair in Cardiovascular Science at the University of Sheffield in 2011, and funded through consecutive BHF programme grants, his group have published >60 papers in high-ranking journals. His work has been recognised by the award of the Medawar Medal (British Transplantation Society), John French Lecture (British Atherosclerosis Society) and Michael Davies Award (British Cardiovascular Society). Evans has supervised 22 PhDs and 13 PDRAs. His team have won numerous prestigious awards and ten of them progressed to faculty positions.
Evans has major leadership roles at the European Society of Cardiology (ESC). He chaired the ESC Working Group for Atherosclerosis leading to senior authorship of four ESC position papers. He was elected ESC Fellow in 2015, joined the Basic Science Council in 2018 and will co-organize the flagship ESC Frontiers meeting in 2021. He has served on funding panels for BHF, MRC, UKRI Future Leaders Fellowships, NC3Rs and was recently appointed to the Board of NC3Rs. He is Chair of AWERB at UoS and is actively involved in public engagement around animal research. He was recently elected Fellow of the Royal Society of Biology.